Novel MDMA Analogue Shows Promise for Rapid PTSD Treatment

Experimental drug TSND-201 significantly reduced PTSD symptoms compared to placebo in phase 2 trial

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

A novel, non-hallucinogenic MDMA analogue called TSND-201 (methylone) has shown statistically significant and clinically meaningful improvement in PTSD symptom severity compared to placebo in a phase 2 randomized, placebo-controlled trial. The drug demonstrated rapid effects that persisted for weeks after the final dose, supporting further development as a potential rapid-acting treatment option for PTSD.

Why it matters

PTSD is a debilitating condition with an urgent unmet need for effective, fast-acting treatments. Currently, only two SSRI medications are FDA-approved for PTSD, but they can have limited effectiveness and slow onset of action. The positive results with TSND-201 suggest it could offer a new rapid-acting therapeutic option for patients suffering from PTSD.

The details

The IMPACT-1 (Part B) study enrolled 65 adults with severe, chronic PTSD who had tried at least one prior PTSD treatment. Participants were randomly assigned to receive either TSND-201 or placebo, consisting of four once-weekly oral dosing sessions. Unlike MDMA-assisted therapy, the current trial tested TSND-201 without structured psychotherapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful 9.64-point greater improvement in CAPS-5 PTSD symptom severity scores with TSND-201 compared to placebo. Significant separation from placebo was observed as early as day 10. TSND-201 also led to significant improvements on secondary measures of PTSD symptoms, function, and depression. Adverse events were generally mild to moderate.

  • The IMPACT-1 (Part B) study results were published online on February 18, 2026 in JAMA Psychiatry.

The players

TSND-201

A novel, non-hallucinogenic, experimental drug that is a beta-ketone analogue of MDMA and is in clinical development for PTSD.

Charles B. Nemeroff, MD, PhD

Professor and chair of the Department of Psychiatry and Behavioral Sciences at the Mulva Clinic for the Neurosciences at UT Health Austin, and a member of the American Psychiatric Association Council on Research.

Matthew W. Johnson, PhD

Senior researcher at the Center of Excellence in Psilocybin Research and Treatment at Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics in Baltimore.

Got photos? Submit your photos here. ›

What they’re saying

“The magnitude of the effect is quite robust, and the separation between the drug treatment and placebo is highly statistically and clinically significant. If these results can be replicated in large phase 3 trials, the pathway for FDA approval would appear to be clear.”

— Charles B. Nemeroff, MD, PhD, Professor and chair, Department of Psychiatry and Behavioral Sciences, Mulva Clinic for the Neurosciences, UT Health Austin, and member of the American Psychiatric Association Council on Research (Medscape Medical News)

“We do not know that neuroplastic effects were responsible for the efficacy seen here, and just because no formal psychotherapy was administered, it does not mean that psychotherapeutic process is not responsible for potential efficacy.”

— Matthew W. Johnson, PhD, Senior researcher, Center of Excellence in Psilocybin Research and Treatment, Sheppard Pratt's Institute for Advanced Diagnostics and Therapeutics, Baltimore (Medscape Medical News)

What’s next

The company plans to launch the phase 3 program of TSND-201 in patients with PTSD in the coming months.

The takeaway

The positive results with the novel MDMA analogue TSND-201 suggest it could offer a promising new rapid-acting treatment option for the debilitating condition of PTSD, which currently has limited effective therapies available.